This section contains information about Galapagos NV’s business for stockholders, potential investors, financial analysts and media.
Do you want to receive our press releases?
Mechelen, Belgium, March 5, 2002 — Galapagos Genomics, the Belgian/Dutch functional genomics company, today announced the completion of a Euro21.4 million private placement. This first…
Mechelen, Belgium, January 23, 2002 — Galapagos Genomics NV, the Belgian functional genomics company, today announced that it has been awarded US Patent No. 6,340,595…
Mechelen, Belgium, January 23, 2002 — Galapagos Genomics NV, the Belgian functional genomics company, today announced a research collaboration with Exelixis, Inc., for the use…
Under the terms of the agreement, Galapagos will supply Euroscreen with an arrayed collection of secreted proteins and peptides (“peptide library”) from human cells infected…